Humanigen Announces Preclinical Findings Presented on Lenzilumab’s Potential to Optimize CAR-T Therapy – Nasdaq
|
Humanigen Announces Preclinical Findings Presented on Lenzilumab’s Potential to Optimize CAR–T Therapy
Nasdaq Lenzilumab effectively neutralizes GM-CSF. CAR–T cells maintained robust anti-tumor activity in combination with lenzilumab. GM-CSF depletion by lenzilumab may increase CAR-T expansion. BRISBANE, Calif., May 02, 2018 (GLOBE NEWSWIRE) — Humanigen, Inc … |
|
Humanigen Announces Preclinical Findings Presented on Lenzilumab’s Potential to Optimize CAR–T Therapy
GlobeNewswire (press release) Lenzilumab effectively neutralizes GM-CSF. CAR–T cells maintained robust anti-tumor activity in combination with lenzilumab. GM-CSF depletion by lenzilumab may increase CAR-T expansion. BRISBANE, Calif., May 02, 2018 (GLOBE NEWSWIRE) — Humanigen, Inc … |
|
Hackensack Meridian Health Joins NJII’s Cell and Gene Therapy Development Center
PR Newswire (press release) NEWARK, N.J., May 2, 2018 /PRNewswire/ — The New Jersey Innovation Institute (NJII), an NJIT Corporation, has announced that Hackensack Meridian Health has joined its Cell and Gene Therapy Development Center to access the center’s process development … |
|
Hackensack Meridian Health Joins NJII’s Cell and Gene Therapy Development Center
PR Newswire (press release) NEWARK, N.J., May 2, 2018 /PRNewswire/ — The New Jersey Innovation Institute (NJII), an NJIT Corporation, has announced that Hackensack Meridian Health has joined its Cell and Gene Therapy Development Center to access the center’s process development … |
|
Evotec Licenses CRISPR-Cas9 Technology From ERS
GenomeWeb NEW YORK (GenomeWeb) – Evotec said today that it has licensed CRISPR-Cas9 technology from ERS Genomics, expanding its existing service offering in the gene-editing space. The new license from ERS adds to Evotec’s existing CRISPR licenses from the Broad … |